A

Not Applicable

• Conditions: -L03-L088 Other specified local infections of skin and subcutaneous tissue-L02; Other specified local infections of skin and subcutaneous tissue; L02; L088; L03

• Registration Number: PER-006-13
• Lead Sponsor: Cubist Pharmaceuticals, Inc,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-11
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 0

Inclusion Criteria

•1. Written parental (or appropriate legal representative) informed consent prior to any study-related
procedure not part of normal medical care;
2. Written subject assent (as appropriate);
3.1 Male or female between the ages of 1 to 17 years old, inclusive;
The resto of the information is regsiter in the protocol 

Exclusion Criteria

• 1. Investigational drug use (including daptomycin) or participation in any experimental procedure in the
30 days preceding study entry;
2. Known allergy/ hypersensitivity to daptomycin;
3. Known infection caused solely by Gram-negative pathogen(s), fungus(i) or virus(es)
The resto of the information is regsiter in the protocol

Study & Design

• Study Type: Interventional
• Study Design: Not specified